ArticleRevista espanola de salud publica2020
[The cost of vaccination throughout life in Spain].
Article in Revista espanola de salud publica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Causes and consequences of undervaccination in adults.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Cost-benefit analysis of the National Immunization Program in Spain.Human vaccines & immunotherapeutics · 2024Article
- Updating and Refining of Economic Evaluation of Rotavirus Vaccination in Spain: A Cost-Utility and Budget Impact Analysis.Viruses · 2024Article
- Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain.Infectious diseases and therapy · 2024Article
- [Updated cost of vaccinating throughout life in Spain in 2023].Revista espanola de salud publica · 2023Article
- Trends in hospitalization and death rates among patients with head and neck cancer in Spain, 2009 to 2019.Human vaccines & immunotherapeutics · 2022Article
- Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.Human vaccines & immunotherapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe evaluation of vaccination programmes using cost estimation is an essential tool for immunization policy. The aim of this study was to describe the cost of vaccination through-out life in Spain, both in healthy and risk groups persons.
methodsDescription of cost of vaccination following the national immunization programme throughout life agreed for 2019, and the immunization programme for risk groups.
resultsThe expected cost to immunize a healthy person is 726.06 euros for a healthy woman and 625.89 euros for a healthy man, ranging from 982.99 to 1,815 euros per person in risk groups.
conclusionsThe relatively low cost and the important benefits for health of immunization throughout life make this public health measure useful and worthwhile. Evaluation of immunization programmes should be strengthened in order to assure suitable immunization in every stage of life.
Indexed as
Identifiers
32041940PMC11567646What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.